Clinical trials involving patients with heart failure revealed that MR antagonists reduces morbidity and mortality (6) even when the circulating levels of aldosterone are within normal range, highly suggesting that the activation of local renin–angiotensin aldosterone system (RAAS) is an important contributor factor during heart failure. Here, NR3C2 is linked to heart failure.